17 Aug 2017 16:10
The Biotech Growth Trust Plc - Holding(s) in CompanyThe Biotech Growth Trust Plc - Holding(s) in Company
PR Newswire
London, August 17
TR-1: Standard form for notification of major holdings
| NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i | ||||||
| 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: | THE BIOTECH GROWTH TRUST PLC Legal Entity Identifier 549300Z41EP32MI2DN29 | |||||
| 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) | ||||||
| Non-UK issuer | ||||||
| 2. Reason for the notification (please mark the appropriate box or boxes with an “X”) | ||||||
| An acquisition or disposal of voting rights | ||||||
| An acquisition or disposal of financial instruments | ||||||
| An event changing the breakdown of voting rights | ||||||
| Other (please specify)iii: Completion of the court-sanctioned scheme of arrangement and all-share merger under Part 26 of the Companies Act 2006 of Aberdeen Asset Management PLC and Standard Life plc which became effective on 14 August 2017. As a consequence various investment management companies having delegated voting rights across a number of client portfolios have become affiliated entities (per FCA Glossary definition) and threshold limits have been triggered. | X | |||||
| 3. Details of person subject to the notification obligationiv | ||||||
| Name | Aggregate of Standard Life Aberdeen plc affiliated investment management entities with delegated voting rights on behalf of multiple managed portfolios | |||||
| City and country of registered office (if applicable) | Edinburgh, Scotland | |||||
| 4. Full name of shareholder(s) (if different from 3.)v | ||||||
| Name | ||||||
| City and country of registered office (if applicable) | ||||||
| 5. Date on which the threshold was crossed or reachedvi: | 14/08/2017 | |||||
| 6. Date on which issuer notified (DD/MM/YYYY): | 16/08/2017 | |||||
| 7. Total positions of person(s) subject to the notification obligation | ||||||
| % of voting rights attached to shares (total of 8. A) | % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) | Total of both in % (8.A + 8.B) | Total number of voting rights of issuervii | |||
| Resulting situation on the date on which threshold was crossed or reached | 6.23 | 0.00 | 6.23 | 55,839,913 | ||
| Position of previous notification (if applicable) | N/A | N/A | N/A | |||
| 8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii | |||||||||
| A: Voting rights attached to shares | |||||||||
| Class/type of shares ISIN code (if possible) | Number of voting rightsix | % of voting rights | |||||||
| Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) | Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) | Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) | Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) | ||||||
| GB0000385517 | N/A | 3,479,095 | N/A | 6.23 | |||||
| SUBTOTAL 8. A | 3,479,095 | 6.23 | |||||||
| B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) | |||||||||
| Type of financial instrument | Expiration datex | Exercise/ Conversion Periodxi | Number of voting rights that may be acquired if the instrument is exercised/converted. | % of voting rights | |||||
| SUBTOTAL 8. B 1 | |||||||||
| B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) | |||||||||
| Type of financial instrument | Expiration datex | Exercise/ Conversion Period xi | Physical or cash settlementxii | Number of voting rights | % of voting rights | ||||
| SUBTOTAL 8.B.2 | |||||||||
| 9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”) | ||||
| Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii | ||||
| Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary) | X | |||
| Namexv | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold | |
| Standard Life Investments Limited | 2.04 | 0.00 | 2.04 | |
| Standard Life Wealth Limited | 1.36 | 0.00 | 1.35 | |
| Aberdeen Asset Managers Limited | 0.08 | 0.00 | 0.08 | |
| Aberdeen Asset Investments Limited | 2.75 | 0.00 | 2.75 | |
| 10. In case of proxy voting, please identify: | ||||
| Name of the proxy holder | N/A | |||
| The number and % of voting rights held | N/A | |||
| The date until which the voting rights will be held | N/A | |||
| 11. Additional informationxvi | ||||
| As a result of the completion of the court-sanctioned scheme of arrangement and all-share merger under Part 26 of the Companies Act 2006 of Aberdeen Asset Management PLC and Standard Life plc which became effective on 14 August 2017, this notification details the assets under management of the new Combined Group (‘Standard Life Aberdeen plc’) as of the dates noted above. In reference to section 9, the shares detailed are managed by the named discretionary investment management entity within multiple portfolios on behalf of underlying clients, based on investment management agreements whereby the client has delegated the exercise of the voting power to the referenced investment manager. | ||||
| Place of completion | Aberdeen, United Kingdom |
| Date of completion | 16/08/2017 |
Biotech Gwth (BIOG)